替奈普酶与阿替普酶在卒中后3至4.5小时低NHISS评分患者中的比较
本研究为NOR-TEST的预设亚组分析,比较替奈普酶与阿替普酶在缺血性卒中后3至4.5小时、入院NHISS中位数3分的患者中的疗效与安全性。结果显示两组3个月良好功能结局(mRS 0-1)比例分别为57%和53%(OR 1.19;95%CI 0.68-2.10),48小时内颅内出血率分别为5.7%和6.7%(OR 0.84;95%CI 0.26-2.70),3个月死亡率分别为5.7%和4.5%。结论认为替奈普酶至少与阿替普酶同样有效。
要点
- 对于发病3至4.5小时的轻型缺血性卒中患者,替奈普酶在3个月良好功能结局方面不劣于阿替普酶。
- 两组48小时内颅内出血率和3个月死亡率数值接近,安全性相当。
- 排除卒中模拟病及病前mRS>1者后,替奈普酶组良好功能结局比例仍略高(61% vs 57%)。
核心结论
- 在发病3至4.5小时的轻型缺血性卒中患者中,替奈普酶在实现良好临床结局方面至少与阿替普酶同样有效。
研究设计与样本
- 本研究为NOR-TEST随机对照试验的预设亚组分析,比较替奈普酶与阿替普酶在缺血性卒中后3至4.5小时患者中的疗效与安全性。
- 该亚组人群入院NHISS中位数为3(四分位距2-6)。
主要发现
- 意向性治疗分析中,替奈普酶组57%、阿替普酶组53%的患者在3个月达到良好功能结局(mRS 0-1),OR 1.19(95%CI 0.68-2.10)。
- 48小时内颅内出血率替奈普酶组为5.7%,阿替普酶组为6.7%,OR 0.84(95%CI 0.26-2.70)。
- 3个月死亡率替奈普酶组为5.7%,阿替普酶组为4.5%。
- 排除卒中模拟病及病前mRS>1的患者后,良好功能结局比例替奈普酶组为61%,阿替普酶组为57%,OR 1.24(95%CI 0.65-2.37)。
临床怎么用
- 对于发病3至4.5小时的轻型缺血性卒中患者,可考虑使用替奈普酶作为阿替普酶的替代溶栓药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Thrombolysis with alteplase has beneficial effect on outcome and is safe within 4.5 hours. The present study compares the efficacy and safety of tenecteplase and alteplase in patients treated 3 to 4.5 hours after ischemic stroke. Methods- The data are from a prespecified substudy of patients included in The NOR-TEST (Norwegian Tenecteplase Stroke Trial), a randomized control trial comparing tenecteplase with alteplase. Results- The median admission National Institutes of Health Stroke Scale for this study population was 3 (interquartile range, 2-6). In the intention-to-treat analysis, 57% of patients that received tenecteplase and 53% of patients that received alteplase reached good functional outcome (modified Rankin Scale score of 0-1) at 3 months (odds ratio, 1.19; 95% CI, 0.68-2.10). The rates of intracranial hemorrhage in the first 48 hours were 5.7% in the tenecteplase group and 6.7% in the alteplase group (odds ratio, 0.84; 95% CI, 0.26-2.70). At 3 months, mortality was 5.7% and 4.5%, respectively. After excluding stroke mimics and patients with modified Rankin Scale score of >1 before stroke, the proportion of patients with good functional outcome was 61% in the tenecteplase group and 57% in the alteplase group (odds ratio, 1.24; 95% CI, 0.65-2.37). Conclusions- Tenecteplase is at least as effective as alteplase to achieve a good clinical outcome in patients with mild stroke treated between 3 and 4.5 hours after ischemic stroke. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01949948.
引用
- Rønning OM, Logallo N, Thommessen B, et al. Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale. Stroke. 2019. PMID: 30602354. doi:10.1161/STROKEAHA.118.024223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。